SK280989B6 - Spôsob výroby farmaceutického preparátu obsahujúceho zrážací faktor ix - Google Patents

Spôsob výroby farmaceutického preparátu obsahujúceho zrážací faktor ix Download PDF

Info

Publication number
SK280989B6
SK280989B6 SK1633-98A SK163398A SK280989B6 SK 280989 B6 SK280989 B6 SK 280989B6 SK 163398 A SK163398 A SK 163398A SK 280989 B6 SK280989 B6 SK 280989B6
Authority
SK
Slovakia
Prior art keywords
factor
plasma
pharmaceutical preparation
bound
eluted
Prior art date
Application number
SK1633-98A
Other languages
English (en)
Slovak (sk)
Inventor
Yendra Linnau
Maria Sazgary
Original Assignee
Baxter Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Aktiengesellschaft filed Critical Baxter Aktiengesellschaft
Publication of SK280989B6 publication Critical patent/SK280989B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
SK1633-98A 1991-01-25 1992-01-24 Spôsob výroby farmaceutického preparátu obsahujúceho zrážací faktor ix SK280989B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0016391A AT402261B (de) 1991-01-25 1991-01-25 Komplex enthaltend den gerinnungsfaktor ix

Publications (1)

Publication Number Publication Date
SK280989B6 true SK280989B6 (sk) 2000-10-09

Family

ID=3483232

Family Applications (2)

Application Number Title Priority Date Filing Date
SK1633-98A SK280989B6 (sk) 1991-01-25 1992-01-24 Spôsob výroby farmaceutického preparátu obsahujúceho zrážací faktor ix
SK211-92A SK280130B6 (sk) 1991-01-25 1992-01-24 Komplex zrážacieho faktora ix, spôsob jeho výroby,

Family Applications After (1)

Application Number Title Priority Date Filing Date
SK211-92A SK280130B6 (sk) 1991-01-25 1992-01-24 Komplex zrážacieho faktora ix, spôsob jeho výroby,

Country Status (12)

Country Link
US (2) US5281661A (cs)
EP (1) EP0496725B1 (cs)
JP (2) JP2651307B2 (cs)
AT (2) AT402261B (cs)
CA (1) CA2059979C (cs)
CZ (2) CZ154794A3 (cs)
DE (1) DE59207638D1 (cs)
DK (1) DK0496725T3 (cs)
ES (1) ES2098485T3 (cs)
FI (1) FI100111B (cs)
HU (1) HU212362B (cs)
SK (2) SK280989B6 (cs)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2105282C (en) 1991-03-01 2002-09-24 Centeon L.L.C. Preparation of factor ix
DE4342132C1 (de) * 1993-12-10 1994-11-03 Octapharma Ag Verfahren zur Herstellung virusinaktivierte Vitamin K abhängige Plasmakomponenten sowie Protein C und Protein S enthaltender Mittel durch Membran-Chromatographie
EP0716744B1 (en) * 1994-06-30 2001-11-07 Dade Behring Inc. Bioactive porous partition members
US5602037A (en) * 1994-06-30 1997-02-11 Dade International, Inc. Combination reagent holding and test device
US5888826A (en) * 1994-06-30 1999-03-30 Dade Behring Inc. Combination reagent holding and test device
DE19506633A1 (de) * 1995-02-25 1996-08-29 Octapharma Ag Verfahren zur Herstellung von Faktor IX aus biologischen Quellen
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
US5958716A (en) * 1996-06-06 1999-09-28 Dade Behring Inc. Blood factor assay
CN1284881A (zh) * 1997-11-05 2001-02-21 吉富制药株式会社 肝素辅助因子ⅱ制剂及其制备方法
JP4855074B2 (ja) * 2003-09-30 2012-01-18 一般財団法人化学及血清療法研究所 高純度血液凝固ｉｘ因子調製物およびその精製方法
CA2571292C (en) 2004-06-30 2013-05-21 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
JP2008525381A (ja) * 2004-12-23 2008-07-17 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 関心のあるビタミンｋ依存性タンパク質を含んでなる組成物中におけるタンパク質混入物の量の減少
MY157239A (en) 2009-05-27 2016-05-13 Baxalta Inc A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
CN102655853B (zh) 2009-09-17 2015-07-29 巴克斯特卫生保健有限公司 透明质酸酶和免疫球蛋白的稳定的复合制剂及其使用方法
EA032336B1 (ru) 2010-09-17 2019-05-31 Баксалта Инкорпорейтид Стабильная водная иммуноглобулиновая композиция и способ стабилизации иммуноглобулиновой композиции
AU2011343813B2 (en) 2010-12-15 2015-05-21 Takeda Pharmaceutical Company Limited Eluate collection using conductivity gradient
WO2012154272A1 (en) 2011-02-25 2012-11-15 Wellstat Diagnostics, Llc Assays for detecting enzymatic activity
CN121985959A (zh) 2023-09-26 2026-05-05 武田药品工业株式会社 耗减IgA的免疫球蛋白制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2543448A1 (fr) * 1983-04-01 1984-10-05 Rhone Poulenc Spec Chim Procede de fractionnement du plasma
US4820805A (en) * 1983-07-14 1989-04-11 New York Blood Center, Inc. Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US4721572A (en) * 1985-07-12 1988-01-26 Miles Laboratories, Inc. Purfication of blood clotting factors and other blood proteins on non-carbohydrate sulfated matrices
ATE130620T1 (de) * 1986-01-06 1995-12-15 Blood Systems Inc Therapeutisches blutprodukt, mittel und verfahren zu dessen erzeugung.
JPS63108000A (ja) * 1986-05-15 1988-05-12 Green Cross Corp:The 第８因子の精製方法
US4725673A (en) * 1986-08-29 1988-02-16 Alpha Therapeutic Corporation Plasma fraction purification using silica resin bound to a ligand
EP0317376B2 (fr) * 1987-10-23 1996-04-03 Centre Regional De Transfusion Sanguine De Lille Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques
DE3914869C1 (cs) * 1989-05-05 1990-08-09 Biotest Pharma Gmbh, 6072 Dreieich, De

Also Published As

Publication number Publication date
HUT63863A (en) 1993-10-28
ES2098485T3 (es) 1997-05-01
JPH08259449A (ja) 1996-10-08
JP2866047B2 (ja) 1999-03-08
CZ280297B6 (cs) 1995-12-13
ATE146220T1 (de) 1996-12-15
JP2651307B2 (ja) 1997-09-10
US5409990A (en) 1995-04-25
CA2059979C (en) 2003-04-15
FI920342A0 (fi) 1992-01-24
SK280130B6 (sk) 1999-08-06
EP0496725A3 (en) 1993-05-05
US5281661A (en) 1994-01-25
ATA16391A (de) 1996-08-15
EP0496725B1 (de) 1996-12-11
AT402261B (de) 1997-03-25
FI100111B (fi) 1997-09-30
JPH04295432A (ja) 1992-10-20
CA2059979A1 (en) 1992-07-26
DE59207638D1 (de) 1997-01-23
HU9200225D0 (en) 1992-04-28
DK0496725T3 (da) 1997-06-09
CZ280725B6 (cs) 1996-04-17
CS21192A3 (en) 1992-08-12
FI920342L (fi) 1992-07-26
CZ154794A3 (en) 1996-04-17
EP0496725A2 (de) 1992-07-29
HU212362B (en) 1996-06-28

Similar Documents

Publication Publication Date Title
CA2059979C (en) Complex containing coagulation factor ix
EP0792281B1 (en) Process for purification of factor viii
EP0131142A2 (en) Process for recovering a cell wall protein
EP0140386B1 (en) Method for the purification of lpf-ha
Ogawa et al. Purification and some properties of urokinase
EP0391974B1 (en) Process for the purification of vitamin k-dependent blood clotting factors
US5071961A (en) Method of enrichment of coagulation factors ii, vii, ix and x
SK22695A3 (en) Isolation and purification method of proteins dependent from vitamin k
JP3043558B2 (ja) ヒト活性化プロテインｃ調製物及びその製法
US5445958A (en) Process for purifying blood clotting factors
AU3080399A (en) Improved methods for producing factor viii proteins
JPH1075778A (ja) プロトロンビンおよびトロンビンに結合するペプチド
JPS6034916A (ja) 第１ｘ因子および他のビタミンｋ依存性タンパク質の高純度精製
EP0813597B1 (en) A process for the purification of vitamin k dependent coagulation factors by chromatography
Scherberich et al. Bio-and immunospecific affinity chromatography of plasma membrane antigens from human kidney and renal cell carcinoma
Chou et al. Separation of human renal renin and pseudorenin by affinity chromatography on hemoglobin-sepharose-2B
AU627446C (en) Chemical process
Kizuki et al. Porcine pancreatic prokallikrein. II. Purification and some properties of prokallikrein A
JPH0795894A (ja) リポコルチンの精製方法
de Lille llllll" 111 ill Ilill ll| l| lllll lllll|||| l lilil lllll| l|||" II" III lllll| ll|
Mannhalter 4. Therapy with Plasminogen Concentrates: Preliminary Results and Future Strategies
JP2003096094A (ja) プロテインｓの精製法および高比活性プロテインｓ調製物
MXPA97003470A (en) Factor v purification process
CZ2000983A3 (cs) Způsob čištění antithrombinu III